Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis

被引:154
作者
Koning, GA
Schiffelers, RM
Wauben, MHM
Kok, RJ
Mastrobattista, E
Molema, G
ten Hagen, TLM
Storm, G
机构
[1] Univ Utrecht, Dept Pharmaceut, Utrecht Inst Pharmaceut Sci, NL-3508 TB Utrecht, Netherlands
[2] Delft Univ Technol, Delft, Netherlands
[3] Leiden Univ, Med Ctr, Leiden, Netherlands
[4] Univ Groningen, Groningen, Netherlands
[5] Erasmus Univ, Rotterdam, Netherlands
来源
ARTHRITIS AND RHEUMATISM | 2006年 / 54卷 / 04期
关键词
D O I
10.1002/art.21719
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. To investigate whether RGD peptide-exposing long circulating polyethylene glycol (PEG) liposomes (RGD-PEG-L) targeted to alpha v beta 3 integrins expressed on angiogenic vascular endothelial cells (VECs) are able to bind VECs at sites of inflammation and whether such liposomes containing dexamethasone phosphate (DEXP) can be used as carriers to interfere with the development of experimental arthritis. Methods. Binding and internalization of RGDPEG-L were studied by fluorescence-activated cell sorting and confocal microscopy using fluorescently labeled liposomes. Radiolabeled liposomes were used to test in vivo pharmacokinetics and inflammation site targeting in lipopolysaccharide (LPS)-induced inflammation and adjuvant-induced arthritis (AIA) in rats. In vivo inflammation targeting was visualized by intravital microscopy using fluorescently labeled RGD-PEG-L. Therapeutic efficacy of DEXP-encapsulating RGD-PEG-L compared with nontargeted liposomes was evaluated in rats with AIA. Results. RGD-PEG-L bound to and were taken up by proliferating human VECs in vitro. In vivo, increased targeting of radiolabeled RGD-PEG-L to areas of LPS-induced inflammation in rats was observed. Specific association with the blood vessel wall at the site of inflammation was confirmed by intravital microscopy. One single intravenous injection of DEXP encapsulated in RGD-PEG-L resulted in a strong and long-lasting antiarthritic effect in rat AIA. Conclusion. RGD-targeted PEG liposomes represent an endothelial cell-specific drug delivery system that targets VECs at sites of inflammation. Use of these liposomes to deliver DEXP to VECs at arthritis-affected sites proved efficacious in rat adjuvant arthritis. These data indicate that VECs have an essential role in the inflammation process and suggest the possibility of using VEC targeting for therapeutic intervention in inflammatory processes such as arthritis.
引用
收藏
页码:1198 / 1208
页数:11
相关论文
共 51 条
[1]   LIPOSOMES CONTAINING SYNTHETIC LIPID DERIVATIVES OF POLY(ETHYLENE GLYCOL) SHOW PROLONGED CIRCULATION HALF-LIVES INVIVO [J].
ALLEN, TM ;
HANSEN, C ;
MARTIN, F ;
REDEMANN, C ;
YAUYOUNG, A .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1066 (01) :29-36
[2]   Delivery of pharmacologically active dexamethasone into activated endothelial cells by dexamethasone-anti-E-selectin immunoconjugate [J].
Asgeirsdóttir, SA ;
Kok, RJ ;
Everts, M ;
Meijer, DKF ;
Molema, G .
BIOCHEMICAL PHARMACOLOGY, 2003, 65 (10) :1729-1739
[3]   Endothelial adhesion molecules in the development of the vascular tree: the garden of forking paths [J].
Bazzoni, G ;
Dejana, E ;
Lampugnani, MG .
CURRENT OPINION IN CELL BIOLOGY, 1999, 11 (05) :573-581
[4]  
Bendas G, 1998, Pharm Acta Helv, V73, P19, DOI 10.1016/S0031-6865(97)00043-5
[5]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[6]   ADHESION MOLECULES - A NEW TARGET FOR IMMUNOLIPOSOME-MEDIATED DRUG-DELIVERY [J].
BLOEMEN, PGM ;
HENRICKS, PAJ ;
VANBLOOIS, L ;
VANDENTWEEL, MC ;
BLOEM, AC ;
NIJKAMP, FP ;
CROMMELIN, DJA ;
STORM, G .
FEBS LETTERS, 1995, 357 (02) :140-144
[7]  
BOTTCHER CJF, 1961, ANAL CHIM ACTA, V24, P203
[8]  
Brostjan C, 1997, J IMMUNOL, V158, P3836
[9]   Regulation of ICAM-1 by dexamethasone in a human vascular endothelial cell line EAhy926 [J].
BurkeGaffney, A ;
Hellewell, PG .
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 1996, 270 (02) :C552-C561
[10]   Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis [J].
Cañete, JD ;
Pablos, JL ;
Sanmartí, R ;
Mallofré, C ;
Marsal, S ;
Maymó, J ;
Gratacós, J ;
Mezquita, J ;
Mezquita, C ;
Cid, MC .
ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1636-1641